Funder
Bakhtarbioshimi pharmaceutical company
Kermanshah University of Medical Sciences
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference16 articles.
1. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection;Gane;Gastroenterology,2017
2. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses;Mahmud;Sci. Rep.,2018
3. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir;McConachie;Expert Rev. Clin. Pharmacol.,2016
4. Application of TLC densitometric method for simultaneous estimation of the newly co-formulated antiviral agents ledipasvir and sofosbuvir in their tablet dosage form;Salama;Anal. Chem. Lett.,2017
5. Assay and dissolution methods development and validation for simultaneous determination of sofosbuvir and ledipasvir by RP-HPLC method in tablet dosage forms;Hassouna;J. Forensic Sci. Criminal Inv.,2017
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献